ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,954.50
1.59%
US Tech 100
20,332.80
1.61%
Dow Jones
43,840.91
1.39%
Brent Oil
73.045
0.00%
Bitcoin
84,948.50
0.69%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Sanofi (SNY)

  7. Sanofi (SNY) News

SNY

Sanofi (SNY)

Sanofi
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SNY
DateTimeSourceHeadlineSymbolCompany
02/22/20252:20AMGlobeNewswire Inc.Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s DiseaseNASDAQ:SNYSanofi
02/13/20252:11PMEdgar (US Regulatory)Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).NASDAQ:SNYSanofi
02/13/20251:41PMEdgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:SNYSanofi
02/13/202512:23PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SNYSanofi
02/03/202512:14PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SNYSanofi
01/30/20259:50AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SNYSanofi
12/13/202411:07AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SNYSanofi
11/18/202412:23PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SNYSanofi
11/15/202412:59AMGlobeNewswire Inc.Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)NASDAQ:SNYSanofi
11/06/20241:00AMGlobeNewswire Inc.Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic EsophagitisNASDAQ:SNYSanofi
10/28/20245:56PMPR Newswire (Canada)L'immunisation par Beyfortus® pour protéger les nourrissons contre le VRS a commencéNASDAQ:SNYSanofi
10/28/20245:54PMPR Newswire (Canada)Beyfortus® immunization to protect infants from RSV has begunNASDAQ:SNYSanofi
10/25/20246:05AMIH Market NewsCapri Shares Crash 45% After Merger Block; Coursera Falls 18% on Lower Revenue ForecastNASDAQ:SNYSanofi
10/21/20245:47AMIH Market NewsSpirit’s Stock Surges 56% on Refinancing; Starboard Invests in Kenvue; Cigna-Humana Merger Back in NegotiationsNASDAQ:SNYSanofi
10/17/20242:35AMBusiness WireSanofi and Orano Join Forces to Develop Next-generation Radioligand MedicinesNASDAQ:SNYSanofi
10/17/20242:35AMBusiness WireSanofi et Orano Med unissent leurs forces pour développer des radiothérapies internes vectorisées de nouvelle générationNASDAQ:SNYSanofi
10/16/202412:26PMPR Newswire (US)FLUBLOK® (Influenza Vaccine) US label updated with one of Sanofi's largest flu vaccine safety studies in pregnant individualsNASDAQ:SNYSanofi
10/16/20246:00AMPR Newswire (US)Sanofi commits $18 million to Howard University College of Medicine, Meharry Medical College, and Morehouse School of Medicine to increase diversity in clinical studiesNASDAQ:SNYSanofi
10/11/20246:31AMIH Market NewsBP Signals Rising Net Debt; Tesla Slumps; Stellantis CEO Announces Retirement; Berkshire Trims BofA Stake, and MoreNASDAQ:SNYSanofi
09/27/20249:35AMGlobeNewswire Inc.Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPDNASDAQ:SNYSanofi
09/27/20247:00AMGlobeNewswire Inc.Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)NASDAQ:SNYSanofi
09/24/20242:51PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SNYSanofi
09/23/20246:32AMIH Market NewsApollo Eyes $5 Billion Investment in Intel; TSMC and Samsung Explore UAE Chip Projects, and MoreNASDAQ:SNYSanofi
09/20/20247:45AMGlobeNewswire Inc.Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year OldNASDAQ:SNYSanofi
09/16/20248:00AMPR Newswire (US)Sanofi shipping BEYFORTUS® in US to help protect babies against RSV disease; new manufacturing line approved by FDANASDAQ:SNYSanofi
09/13/202412:15PMGlobeNewswire Inc.Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)NASDAQ:SNYSanofi
09/12/20242:37AMBusiness WireAccord de licence entre Sanofi, RadioMedix et Orano Med pour le développement d’une nouvelle génération de radiothérapies internes vectorisées contre les cancers raresNASDAQ:SNYSanofi
09/12/20242:37AMBusiness WireSanofi, RadioMedix, and Orano Med Announce Licensing Agreement on Next-Generation Radioligand Medicine for Rare CancersNASDAQ:SNYSanofi
08/13/20249:06AMEdgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:SNYSanofi
08/13/20246:30AMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SNYSanofi
 Showing the most relevant articles for your search:NASDAQ:SNY

Your Recent History

CSE
RGX
Regenx Tech
NASDAQ
HWH
HWH
NYSE
TPX
Tempur Sealy
NASDAQ
AVPT
AvePoint
BOV
E1RI34
Telefonaktiebolaget L M ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads